Results 41 to 50 of about 197,589 (314)

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
Jens Huober, Reinisch, Mattea, Sibylle Loibl, Silvia Darb-Esfahani, Michael Untch, Hans Tesch, Martin-Leo Hansmann, Jan C Brase, Knut Engels, Judith Prinzler, Keyur Mehta, Minckwitz, Gunter von, Brase, Jan C., Kronenwett, Ralf, Hansmann, Martin-Leo, Huober, Jens, Engels, Knut, Solbach, Christine, Tesch, Hans, Carsten Denkert, Denkert, Carsten, Gunter von Minckwitz, Bruno V Sinn, Loibl, Sibylle, Mattea Reinisch, Peter A Fasching, Sinn, Bruno V., Ralf Kronenwett, Christine Solbach, Prinzler, Judith, Mehta, Keyur, Fasching, Peter Andreas, Untch, Michael, Denkert, Carsten Michael, Darb-Esfahani, Silvia   +34 more
core   +1 more source

HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer

, 2020
Human epidermal growth factor receptor 2 (HER2) is a biomarker in breast cancer, and its overexpression is required to initiate therapies using HER2-targeted antibodies.
Ashwin Ragupathi (5563616), Nerissa T. Viola, Patricia M. R. Pereira, Komal Mandleywala, Patricia M. R. Pereira (8157894), Jason S. Lewis, Ashwin Ragupathi, Komal Mandleywala (8157900), Shayla Shmuel, Nerissa T. Viola (8157903), Shayla Shmuel (8157897), Jason S. Lewis (254218)   +11 more
core   +1 more source

Therapeutic targeting of Integrin v 6 in breast cancer [PDF]

, 2014
BACKGROUND: Integrin ?v?6 promotes migration, invasion, and survival of cancer cells; however, the relevance and role of ?v?6 has yet to be elucidated in breast cancer.METHODS: Protein expression of integrin subunit beta6 (?6) was measured in breast ...
Thomas, GJ, Louise Jones, J., Eccles, D, Hart, I. R. (Ian R.), Kendrew, Jane, Chou, Patrick, Gillett, C., Jordan, L, Violette, S., Brentnall, A., Duffy, S.W., Warwick, J., Thomas, Gareth J., Saha, A, Hart, I.R., Bowen, R, Barry, S.T., Green, Andrew R, Gillett, Cheryl, Vallath, S, Bowen, R., Haider, Syed, Barry, Simon T, Moore, K.M., Hart, Ian R., Barry, Simon T., Gabe, R., Haider, S., Chelala, C, Jones, J.L., Thomas, Gareth J, Chelala, C., Eccles, Diana, Ellis, Ian O, Kendrew, J., Green, Andrew R., Weinreb, PH, Jones, JL, Chou, P, Vallath, S., Marshall, John F., Jordan, L., Brouilette, Kellie, Kendrew, J, Duffy, Stephen W, Ellis, I.O., Quinlan, P., Quinlan, P, Gabe, R, Haider, S, Moore, Kate M, Jordan, Lee, Hart, Ian R, Marshall, J.F., Brentnall, Adam, Moore, KM, Jones, J. Louise, Barry, ST, Gillett, C, Warwick, J, Thompson, Alastair M, Weinreb, Paul H, Vallath, Sabari, Chou, P., Green, AR, Thompson, A.M., Thompson, AM, Saha, Antonio, Violette, Sheila, Tapper, W.J., Hart, IR, Ellis, IO, Jones, J Louise, Tapper, William J., Brentnall, A, Weinreb, P.H., Brouilette, K., Tapper, Will, Gabe, Rhian, Thompson, Alastair M., Saha, A., Eccles, D., Violette, Shelia, Tapper, William J, Marshall, JF, Thomas, G J., Weinreb, Paul H., Duffy, Stephen W., Moore, Kate M., Brouilette, K, Green, A.R., Quinlan, Phillip, Duffy, SW, Ellis, Ian, Warwick, Jane, Marshall, John F, Bowen, Rebecca, Chelala, Claude, Tapper, WJ, Violette, S, Ellis, Ian O.   +100 more
core   +1 more source

Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

Molecular Oncology, EarlyView.
This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel, Peyman Zarrineh, Nathnael T. Tuffa, Jigar H. Sheth, Sumitra Mohan, Mudassar Iqbal, Sankari Nagarajan   +6 more
wiley   +1 more source

Retrospective Analysis of Transcriptomic Differences between Triple-Negative Breast Cancer (TNBC) and non-TNBC

European Journal of Biology
Objective: Triple-negative breast cancer (TNBC), which has no expression of estrogen receptor, progesterone receptor and HER2, is an aggressive subgroup.
Çağlar Berkel
doaj   +1 more source

Quinazolin-4(3H)-one based potential multiple tyrosine kinase inhibitors with excellent cytotoxicity

Journal of Enzyme Inhibition and Medicinal Chemistry, 2021
A series of quinazolin-4(3H)-one derivatives were synthesised and evaluated for their cytotoxicity against human Caucasian breast adenocarcinoma (MCF-7) and human ovarian carcinoma (A2780) cell lines.
Tebyan O. Mirgany, Ashraf N. Abdalla, Md Arifuzzaman, A. F. M. Motiur Rahman, Huda S. Al-Salem   +4 more
doaj   +1 more source

HER2-Positive Gastroesophageal Cancers Are Associated with a Higher Risk of Brain Metastasis

, 2022
Brain metastasis from gastroesophageal adenocarcinomas (GOCs) is a rare but a devastating diagnosis. Human epidermal growth factor receptor 2 (HER2) is a prognostic and predictive biomarker in GOCs.
A Mukhtiar (22506929), Marie Ranson (19586413), A Naveed (16204115), Lorraine Chantrill (19586761), Ann-Katrin Piper (19584151), TM Becker (17906066), Gary Tincknell (19586755), J Nankervis (9851816), Kara Perrow (19585660), Morteza Aghmesheh (19587223), Daniel Brungs (19585414)   +10 more
core   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source

Effect of the Ethanolic Extract of Eryngium billardieri on the Viability of the Triple-Negative Breast Cancer Cell Line (MDA-MB-231) and CDKN2A, MDM2, and HER2 Expression

European Journal of Biology
Objective: Currently, treating triple-negative breast cancer (TNBC) poses a significant challenge. Eryngium billardierei is widely employed as a medicinal plant, particularly for the treatment of cancers.
Azadeh Hekmat, Elaheh Ghanbari, Saeed Hesami Tackallou   +2 more
doaj   +1 more source

HER2-low in gastroesophageal adenocarcinoma: a real-world pathological perspective [PDF]

, 2022
openIntroduction: Trastuzumab in combination with cytotoxic chemotherapy is the first-line therapy of choice in HER2-overexpressing metastatic gastroesophageal cancers.
RIGHETTO, ANNA
core